OmniAb, Inc. (OABI) Earnings Signals & AI Vibe Check

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, OmniAb, Inc.'s filing signal continuing negative.

OmniAb, Inc. is a biotechnology company that licenses its proprietary antibody discovery technology platform, powered by "Biological IntelligenceTM," to pharmaceutical and biotech companies and academic institutions. The platform utilizes genetically engineered transgenic animals, including OmniRat(R), OmniChicken(R), and OmniMouse(R), to create diverse antibody repertoires with human sequences for therapeutic development. OmniAb offers integrated end-to-end capabilities and customizable solutions, leveraging AI and machine learning tools like OmniDeepTM and a bioinformatics portal called OmniHubTM. Its business model generates revenue through upfront access fees, service revenue, milestones, and royalties on commercial sales, aiming to accelerate drug discovery and improve success rates for its partners. As of December 31, 2025, the company had 107 active partners and 407 active programs, with 27 OmniAb-derived antibodies in clinical development.

Revenue is primarily driven by license and milestone payments from partners, as well as service revenue for research activities. Long-term value is expected to be driven by royalties on net sales of partner products.